Abstract:
Objective The clinical treatment results of 43 patients with angiosarcoma were retrospectively analyzed and compared to determine the predictive factors of the results, so as to help clinicians choose a more appropriate plan for patients.
Methods The clinical data of patients with angiosarcoma admitted to Peking University Cancer Hospital & Institute from January 2000 to March 2021 were collected. SPSS 20.0 software was used for statistical univariate and multivariate analysis. The main efficacy indexes included progression-free survival (PFS) and overall survival (OS) , including inpatient, outpatient and telephone follow-up, until May 2022.
Results During the follow-up period, 21 patients (49%) died, and 22 patients (51%) survived. The median follow-up time of the whole case was 52 months (range: 6-131 months), and the median PFS was 16 months, OS was 52 months, PFS of 1 year, 3 years and 5 years were 55.6%, 34.3% and 22.2%; respectively, OS was 93%, 61.1% and 49.7%. Univariate analysis: The location, depth, grade and treatment of tumor were related to PFS. Tumor depth, ulceration, grade and treatment were related to OS. Multivariate analysis: tumor depth and treatment were independent prognostic factors of PFS; tumor depth, ulceration and grade were independent prognostic factors of OS.
Conclusions Angiosarcoma is based on surgical treatment, but blind and unplanned surgery should be avoided. Neoadjuvant therapy can benefit patients. Chemotherapy is dominated by taxanes and anthracyclines. For locally advanced patients, preoperative transformation therapy can be performed and radiotherapy is helpful to improve the local control rate. We should pay attention to the comprehensive treatment of surgery, chemotherapy and radiotherapy.
下载: